Dataproducts agrees to be acquired by Hitachi venture for $160 million

Article Abstract:

Two affiliates of Hitachi Ltd - Hitachi Koki Co and Nissei Sangyo Co - will acquire computer printer manufacturer Dataproducts Corp. The price will be $160 million. Hitachi Koki Co and Nissei Sangyo Co will form a joint venture and make a $10 per share offer for Dataproducts' outstanding stock. The agreement resolves Dataproducts' two-year-long search for a strategic merger or acquisition. Since 1988, Dataproducts has fended off a hostile suitor, looked for a buyer that could infuse it with capital, and sold its headquarters and manufacturing operations, using the money to repurchase 20 percent of its stock. Dataproducts posted 1989 sales of $353 million and has a strong position in the US and Canada. Industry analysts believe that the $10-per-share offer is low.

Mergers, acquisitions and divestments, Computer peripherals industry, Manufacturers, Printers, Acquisition, Dataproducts Corp., DPC, Hitachi High-Technologies Corp., Hitachi Koki Company Ltd.

Hong Kong's Video Technology bets on return to public fold in London

Article Abstract:

Video Technology Group Ltd delisted its stock from the Hong Kong Stock Exchange in Jul 1990, and the company hopes to be listed on the London Stock Exchange in Oct 1991. Video Technology, which once was a manufacturer of video games, is now one of the world's foremost computer-video companies. Because Hong Kong will revert to Chinese control in 1997, price-earnings ratios on the Hong Kong Stock Exchange were low. Analysts see Video Technologies' changeover to the London exchange as a good move, but they say the stock will cost more there. Even so, many believe that the company's stock will be worth its higher price.

Stock-exchange, Stock exchanges, Membership, Hong Kong, Securities, London Stock Exchange PLC, Video monitors, Stock Exchange of Hong Kong Ltd., Stock markets, Monitors, Stock Market, Stock, Displays, Video Technology Group Ltd.

Amgen abandons development work on clotting drug

Article Abstract:

Amgen Inc. has stopped development work on an experimental clotting drug. The drug was once considered to be a major discovery in the competition to produce a blood-clotting drug. In 1994, Amgen purchased the rights to two discoveries of a protein that seemed to control platelets, or tiny blood-clotting cells. However, the company stopped work on megakaryocyte growth and its MGDF development factor. This reflected the difficulties of bringing a new drug to the marketplace.

Comment:

Amgen Inc. stops development work on an experimental clotting drug

United States, Research and Development in the Physical, Engineering, and Life Sciences, Product information, Science & research, Company Planning/Goals, New Products/Services, Biological Product (except Diagnostic) Manufacturing, Antihemophiliac Factor, Heart, Lung & Blood Disease R&D, Medical research, Amgen Inc., Factor VIII, Article